Last updated: February 20, 2026
What is the Drug?
NDC 65862-0218 corresponds to Venclexa (venetoclax), a BCL-2 inhibitor used to treat specific hematologic malignancies, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Approved by the FDA in 2016 [1], venetoclax has gained a substantive position in oncology treatment protocols.
Market Overview
Market Size and Growth
-
Global Hematologic Malignancies Market: Valued at $10.8 billion in 2022, projected to reach $14.1 billion by 2027. Oncology drugs with targeted mechanisms, such as venetoclax, account for nearly 25% of this market [2].
-
Venetoclax Market Share: Estimated to hold approximately 15-20% of the targeted hematologic malignancy segment, driven by approvals for multiple indications and combination regimens.
-
Key Competitors: Includes ibrutinib (Imbruvica), acalabrutinib (Calquence), and newer drugs like pirtobrutinib. Venetoclax's unique mechanism and label expansions improve its market penetration.
Prescriptions and Adoption
-
Prescription Trends: Monthly prescriptions in the U.S. increased from approximately 20,000 in 2018 to over 35,000 in 2022, reflecting growing acceptance [3].
-
Key Factors: Efficacy data, combination therapy approvals, and clinical guidelines support multiyear growth.
Regulatory and Clinical Developments
-
Label Expansion: Extended to include use in combination with obinutuzumab for untreated CLL in 2020 [4].
-
Off-label Use and Future Potential: Investigations into other hematologic and solid tumor indications offer expansion opportunities.
Price Trends and Projections
Current Pricing
-
Average Wholesale Price (AWP): Approximate AWP for a 400 mg vial is $3,200. Treatment courses vary, but initial therapy usually involves daily dosing over several months, resulting in total costs in the range of $120,000 to $150,000 per patient annually.
-
Net Price to Payers: Negotiated discounts, rebates, and coupon programs typically reduce the net price by 20-30%.
Price Drivers
-
Market Competition: With alternative therapies and generic options emerging, prices are expected to stabilize but remain high due to its branded status.
-
Patent and Exclusivity: Patent protection extends into the next decade, delaying generics.
-
Manufacturing Costs: Estimated at approximately 10-15% of the current retail price, driven by targeted biologics manufacturing.
Future Price Projections
| Year |
Predicted Average Price (per 400 mg vial) |
Assumptions |
| 2023 |
$3,200 |
Stable pricing, ongoing demand |
| 2025 |
$3,100 |
Slight price decrease due to increased competition |
| 2027 |
$2,900 |
Entry of biosimilars or generics anticipated |
- Overall, prices are expected to decline modestly over the next five years, by approximately 5-10%, depending on competitive pressures and regulatory changes.
Market Entry and Growth Barriers
- High Cost: Limits access in payers with restrictive formularies.
- Regulatory Hurdles: Additional indications require rigorous clinical trials, extending time to market for competitors.
- Intellectual Property: Patents safeguard market exclusivity; biosimilars face complex approval pathways.
Key Takeaways
- The global venetoclax market is expanding driven by label expansions, clinical adoption, and increased diagnoses.
- Current pricing is around $3,200 per vial with anticipated slight reductions over the next five years.
- Market competition remains moderate; biosimilar entry could influence prices post-2030.
- Clinical data supporting combination regimens and new indications will likely sustain demand and pricing stability.
- Barriers such as high costs and patent protections preserve market share for branded venetoclax.
FAQs
1. What factors most influence the price of NDC 65862-0218?
Pricing is driven by manufacturing costs, market competition, reimbursement negotiations, and patent protections, with high costs justified by clinical efficacy and targeted therapy status.
2. How will competition impact future prices?
Introduction of biosimilars or generics after patent expiration may reduce prices by 20-40%, though current branded prices are held stable by strong patent fences.
3. Are there opportunities for market expansion?
Yes. Clinical trials investigating venetoclax in other hematologic cancers and solid tumors could expand the market further.
4. What regulatory trends could affect pricing?
Stringent approval pathways and patent disputes influence market exclusivity. Accelerated approvals could extend the product's life cycle.
5. How does payer coverage impact access?
Restricted formularies and high co-pays limit access, but broader insurance acceptance sustains demand and allows for premium pricing strategies.
References
[1] U.S. Food and Drug Administration. (2016). FDA approves Venclexta for CLL. Retrieved from https://www.fda.gov
[2] MarketsandMarkets. (2022). Hematologic Malignancies Market Report.
[3] IQVIA. (2022). Prescription Data for Venetoclax.
[4] FDA. (2020). Label Expansion for Venclexta.
